Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
Article Category: Research Article
Published Online: Aug 09, 2021
Page range: 12 - 21
Received: Jul 05, 2019
Accepted: Nov 05, 2019
DOI: https://doi.org/10.2478/fco-2019-0015
Keywords
© 2021 Engy M Aboelnaga et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose.
Patients and methods
Patients were enrolled in two groups. Group 1 included 21 patients who received the standard dose of capecitabine (1250 mg/m2 twice daily [BID] for 14 days), while the patients in group 2 (19 patients) received lower dose of capecitabine (850 mg/m2 BID for 14 days) every 3 weeks.
Results
In group 1, dose reduction was reported in 12 (57.1%) patients versus 1 patient in group 2 (5.3%;
Conclusions
A lower dose of capecitabine provides MBC patients with an active therapy that can be continued for prolonged periods to achieve long-term disease control without compromising its antitumor activity.